EP1874271A1 - Compositions a liberation modifiee contenant un derive de fluorocytidine pour le traitement du cancer - Google Patents

Compositions a liberation modifiee contenant un derive de fluorocytidine pour le traitement du cancer

Info

Publication number
EP1874271A1
EP1874271A1 EP06749864A EP06749864A EP1874271A1 EP 1874271 A1 EP1874271 A1 EP 1874271A1 EP 06749864 A EP06749864 A EP 06749864A EP 06749864 A EP06749864 A EP 06749864A EP 1874271 A1 EP1874271 A1 EP 1874271A1
Authority
EP
European Patent Office
Prior art keywords
composition
modified release
dosage form
capecitabine
fluorocytidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06749864A
Other languages
German (de)
English (en)
Other versions
EP1874271A4 (fr
Inventor
Scott Jenkins
Gary Liversidge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharma International Ltd
Original Assignee
Elan Pharma International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma International Ltd filed Critical Elan Pharma International Ltd
Publication of EP1874271A1 publication Critical patent/EP1874271A1/fr
Publication of EP1874271A4 publication Critical patent/EP1874271A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to multiparticulate modified release compositions comprising fluorocytidine derivatives, such as capecitabine, that are suitable for use in the treatment of cancer.
  • the present invention relates to novel dosage forms for the controlled delivery of fluorocytidine derivatives, such as capecitabine.
  • the invention relates to a dosage package designed to enhance patient compliance and therapeutic outcomes.
  • 5-fluorouracil also referred to as 5 -FU prodrugs
  • 5 -FU prodrugs are useful as anti-tumor agents.
  • bioconversion efficiency of 5-FU precursors is poor for the treatment of patients suffering from tumors due to intestinal and immunosuppressive toxicities. Modifications of such 5-FU precursors have led to the development of fluorocytidine derivatives which exhibit improved bioconversion efficiency and toxicity. Fluorocytidine derivatives have been described in, for example, U.S. Patent No.
  • N 4 -(substituted- oxycarbonyl)-5'-deoxy-5-fluorocytidine derivatives a process for their manufacture, antitumor compositions comprising said derivatives and their use in the treatment of tumors in a host.
  • Capecitabine is a fluorocytidine derivative with the chemical name 5'deoxy-5-fluoro- N-[(pentyloxy)carbonyl]-cytidine.
  • Capecitabine has a molecular weight of 359.35 and has the following structural formula:
  • Capecitabine is a white to off-white crystalline powder with an aqueous solubility of
  • Capecitabine is enzymatically converted to 5-FU in vivo. Capecitabine is readily absorbed from the gastrointestinal tract. In the liver, a 60 kDa carboxylesterase hydrolyzes much of the compound to 5 '-deoxy-5 -fluorocytidine (5'-DFCR). Subsequently, cytidine deaminase, an enzyme found in most tissues including tumors, converts 5'-DFCR to 5'deoxy- 5-fluorouridine (5'-DFUR). Thymidine phosphorylase then hydrolyzes 5'-DFUR to the active drug 5'-FU. Many tissues express thymidine phosphorylase. Human carcinomas, however, express the enzyme at higher concentrations than surrounding normal tissues.
  • FdUMP 5-fluoro-2'-deoxyuridine monophosphate
  • FUTP 5-fluoruridine triphosphate
  • FdUMP and the folate cofactor, N 5"10 - methylenetetrahydrofolate bind to thymidylate synthase (TS) to form a covalently bound ternary complex. This binding inhibits the formation of thymidylate from 2'-deoxyuridylate.
  • Thymidylate is the necessary precursor of thymidine triphosphate, which is essential for the synthesis of DNA. Hence, a deficiency of thymidylate can inhibit cell division.
  • FUTP uridine triphosphate
  • UDP uridine triphosphate
  • Capecitabine is regarded as a fluorocytidine derivative with high therapeutic value based on its susceptibility to hepatic carboxylesterase, oral bioavailability in monkeys and efficacy in a human cancer xenograft. Capecitabine given orally yielded substantially higher concentrations of 5-FU within tumors than in plasma or normal muscle tissue. The tumor 5- FU levels were also much higher than those achieved by intraperitoneal administration of 5- FU at equi-toxic doses.
  • This tumor selective delivery of 5-FU ensured greater efficacy and a more favorable safety profile than with other fluoropyrimidines.
  • capecitabine was more effective at a wider dose range and had a broader spectrum of anti-tumor activity than 5-FU, UFT or its intermediate metabolite 5'- DFUR.
  • the susceptibility of the xenografts to capecitabine correlated with tumor dThdPase levels.
  • the conversion of 5'-DFUR to 5-FU by dThdPase in tumor was insufficient in a xenograft model refractory to capecitabine.
  • capecitabine was enhanced by dThdPase up-regulators, such as by taxanes and cyclophosphamide and by X-ray irradiation.
  • the efficacy of capecitabine may, therefore, be optimized by selecting the most appropriate patient population based on dThdPase status and/or by combining it with dThdPase up-regulators.
  • Capecitabine has additional characteristics not found with 5-FU, such as potent anti-metastatic and anti-cachectic actions in mouse tumor models. Based on these profiles, capecitabine may have substantial potential in cancer treatment.
  • Capecitabine is offered under the registered trademark XELOD A ® by Hoffman-La Roche Inc. of Nutley, New Jersey.
  • XELODA ® is supplied as biconvex, oblong film-coated tablets for oral administration in dosages of 150 mg and 500 mg of capecitabine.
  • the film coating contains hydroxypropyl methylcellulose, talc, titanium dioxide, and synthetic yellow and red iron oxides.
  • XELODA ® has been proven to be effective in the treatment of colorectal cancer and breast cancer.
  • XELODA ® is indicated as a first-line treatment of patients with metastatic colorectal cancer when treatment with fluoropyrimidine therapy alone is preferred.
  • the recommended dose of XELOD A ® is 1250 mg/m 2 administered orally twice daily (morning and evening; equivalent to 2500 mg/ m 2 total daily dose) for 2 weeks followed by a 1-week rest period given as 3-week cycles.
  • XELODA ® tablets should be swallowed with water within 30 minutes after a meal, hi combination with doctaxel, the recommended dose of XELODA ® is 1250 mg/m 2 twice daily for 2 weeks followed by a 1-week rest period, combined with docetaxel at 75 mg/m 2 as a 1-hour intravenous infusion every 3 weeks.
  • Fluorocytidine derivatives are of high therapeutic value for the treatment of cancer. Given that fluorocytidine derivatives, such as capecitabine, require oral administration twice daily, strict patient compliance is a critical factor in the efficacy of fluorocytidine derivatives in the treatment of cancer. Moreover, such frequent administration often requires the attention of health care workers and contributes to the high cost associated with treatments involving fluorocytidine derivatives, such as capecitabine. Thus, there is a need in the art for fluorocytidine derivative compositions which overcome these and other problems associated with their use in the treatment of cancer.
  • a multiparticulate modified release composition comprising a fluorocytidine derivative that is designed to release all of the active ingredient at about six to about twelve hours after administration.
  • an immediate release dosage form comprising a fluorocytidine derivative
  • the resulting plasma profile is substantially similar to the plasma profile produced by the administration of two or more immediate release dosage forms given sequentially, such as the plasma profile obtained by the twice a day dosing of XELOD A ® .
  • the compositions of the present invention utilize a modified release feature to allow dosing less frequently than with conventional forms of fluorocytidine derivatives which increases patient convenience and compliance.
  • the modified release may be achieved by the use of formulations such as, for example, erodable formulations, diffusion controlled formulations or osmotic controlled formulations.
  • the present invention relates to a multiparticulate modified release composition that, in operation, delivers a fluorocytidine derivative in a pulsatile manner.
  • the composition of the present invention releases the active ingredient at about six to about twelve hours after administration so as to mimic the plasma profile obtained if that dose had been administered in the morning.
  • the multiparticulate modified release composition comprises a fluorocytidine derivative, preferably capecitabine.
  • the modified release may be achieved by the use of a modified release coating, a modified release matrix material, or both.
  • the composition in operation delivers the fluorocytidine derivative in a unimodal pulsatile manner.
  • Preferred modified release components comprise erodable formulations, diffusion controlled formulations and osmotic controlled formulations.
  • the composition contains a fluorocytidine derivative in an amount from about 0.1 mg to about 1 g.
  • an oral dosage form comprising the multiparticulate modified release composition of the present invention.
  • the dosage forms may be provided in any suitable form such as, for example, in hard or soft gelatin capsules, or as tablets.
  • a dosing package comprising one or more dosage forms of the present invention packaged together with one or more immediate release forms comprising a fluorocytidine derivative.
  • the present invention further provides a method for the treatment of a cancer comprising the step of administering a therapeutically effective amount of the composition of the present invention to a cancer patient in need thereof.
  • Advantages of the present invention include reducing the dosing frequency required by conventional multiple immediate release dosage regimes while still maintaining the benefits derived from a pulsatile plasma profile.
  • a formulation which may be administered at reduced frequency is advantageous in terms of patient compliance.
  • the reduction in dosage frequency made possible by utilizing the present invention would contribute to reducing health care costs by reducing the amount of time spent by health care workers on the administration of drugs.
  • pill refers to a state of matter which is characterized by the presence of discrete particles, pellets, beads or granules irrespective of their size, shape or morphology.
  • multiparticulate as used herein means a plurality of discrete or aggregated particles, pellets, beads, granules or mixture thereof, irrespective of their size, shape or morphology.
  • modified release means a release which is not immediate and is taken to encompass controlled release, sustained release and delayed release.
  • time delay refers to the duration of time between administration of the composition and the release of the active ingredient therefrom.
  • the term "active ingredient” includes one or more fluorocytidine derivatives, preferably capecitabine.
  • the fluorocytidine derivative can be included in a microparticulate drug delivery system in which the fluorocytidine derivative is, or is entrapped within, encapsulated by, attached to, or otherwise associated with, a particulate.
  • the particulates of the present invention have a modified release component that may comprise a modified release coating, a modified release matrix material, or both.
  • the modified release particulates of the present invention may be also provided in the forms disclosed in the United States Patent No. 6,228,398 to Devane et al. which is incorporated by reference herein in its entirety.
  • the composition of the present invention delivers the fluorocytidine derivative in a unimodal manner.
  • the modified release of the fluorocytidine derivative from the composition maybe accomplished by the use of a coating, or a matrix material, or both, and results in a time delay of about six to about twelve hours between administration and the release of the fluorocytidine derivative.
  • the duration of the time delay may be varied by altering the composition and/or the amount of the modified release coating and/or altering the composition and/or amount of modified release matrix material utilized.
  • Suitable formulations for use in varying the time delay include erodable formulations, diffusion controlled formulations and osmotic controlled formulations. By use of such formulations, the duration of the time delay can be designed to produce a desired plasma profile.
  • the composition can be in the form of an erodable formulation in which the structural integrity of the particulates deteriorates within the body over time.
  • the active ingredient is released by the degradation of the modified release coating and/or the matrix materials by the action of human ingestion over a period of time.
  • the composition can be in the form of a diffusion controlled formulation in which the particulates are dispersed in a liquid medium.
  • a diffusion controlled formulation in which the particulates are dispersed in a liquid medium.
  • the composition can be in the form of an osmotic controlled formulation in which the release of the active ingredient from the composition is controlled by osmosis.
  • the delivery system comprises a core that is free of swellable polymers and comprises nonswelling solubilizing agents and wicking agents.
  • the solubilized therapeutic agent is delivered through a passageway in the semipermeable coating of the tablet.
  • composition may further comprise additional components such as, for example, an enhancer compound or a sensitizer compound in order to modify the bioavailability or the therapeutic effect of the fluorocytidine derivative.
  • additional components such as, for example, an enhancer compound or a sensitizer compound in order to modify the bioavailability or the therapeutic effect of the fluorocytidine derivative.
  • enhancer refers to a compound which is capable of enhancing the absorption and/or bioavailability of an active ingredient by promoting net transport across the gastro-intestinal tract in an animal, such as a human.
  • Suitable enhancers include, either alone or in combination, medium chain fatty acids as well as salts, esters, ethers and other derivatives thereof including glycerides and triglycerides; ionic and non-ionic surfactants such as those that can be prepared by reacting ethylene oxide with a fatty acid, a fatty alcohol, an alkylphenol or a sorbitan or glycerol fatty acid ester; cytochrome P450 inhibitors; bile salts and acids: micelles chelators; P-glycoprotein inhibitors and the like.
  • the plasma profile associated with the administration of the composition may be described as "pulsatile profile" in which one or more peaks of plasma concentration of an active ingredient are observed.
  • a pulsatile profile containing one peak may be described as "unimodal,” and a pulsatile profile containing two peaks separated by a lower concentration trough may be described as “bimodal,” and a pulsatile profile containing more than two peaks in which each adjacent pair is separated by a lower concentration trough may be described as "multimodal.”
  • the active fluorocytidine derivative is capecitabine and the composition, in operation, delivers the capecitabine in a unimodal manner.
  • the active fluorocytidine derivative is capecitabine and the modified release composition is co-administered in the evening with an immediate release form of capecitabine and produces a plasma profile which substantially mimics the plasma profile obtained by the sequential administration of two immediate release doses as, for instance, in a typical anti-cancer drug treatment regimen.
  • the release characteristics of the composition may be varied by, for example, modifying the amount and/or type of coating and/or matrix material used in the composition.
  • the release profiles may be further controlled by the selective use of erodable formulations, diffusion controlled formulations or osmotic controlled formulations.
  • the plasma concentration curve produced by the administration of the composition may be varied by, for example, modifying the amount and/or type of coating and/or matrix material used in the composition.
  • the pulses in the plasma profile produced by the concurrent administration of modified release and immediate release forms may be well-separated and clearly defined (e.g., when the time delay of the modified release composition is long) or the pulses may be superimposed to a degree (e.g., when the time delay of the modified release composition is short).
  • the modified release composition according to the present invention has a single modified release component in which the modified release is realized by the use of a modified release coating, a modified release matrix material, or both.
  • co-administration of such a modified release composition with an immediate release form results in a pulsatile plasma profile characterized by a first peak in the plasma profile associated with the immediate release form and a second peak in the plasma profile associated with the modified release component.
  • Embodiments of the invention in which more than one modified release component is present exhibit additional peaks in the plasma profile.
  • an immediate release form and at least one modified release form is advantageous when it is desirable to deliver two (or more) pulses of active ingredient without the need for sequential administration of two (or more) dosage units.
  • a typical treatment regime using capecitabine consists of administration of two doses of an immediate release dosage formulation given about 6 to about 12 hours apart. This type of regime has been found to be therapeutically effective and is widely used.
  • coating materials suitable for use in the practice of the invention include polymer coating materials, such as cellulose acetate phthalate, cellulose acetate trimaletate, hydroxypropylmethylcellulose phthalate, poly(vinyl acetate) phthalate, ammonio methacrylate copolymers such as those sold under the Trade Mark Eudragit ® RS and RL, poly(acrylic acid) and polyacrylate and methacrylate copolymers such as those sold under the Trade Mark Eudragit ® S and L, polyvinyl acetaldiethylamino) acetate, hydroxypropylmethylcellulose acetate succinate, shellac, hydrogels and gel-forming materials such as carboxyvinyl polymers, sodium alginate, sodium carmellose, calcium carmellose, sodium carboxymethyl starch, polyvinyl alcohol), hydroxyethylcellulose, methylcelMose, gelatin
  • polyvinylpyrrolidone m. wt. ⁇ 10 k-360 k
  • a swellable mixture of agar and carboxymethylcellulose copolymers of maleic anhydride and styrene, ethylene, propylene or isobutylene, polysaccharides such as acacia, karaya, tragacanth, algins and guar, polyacrylamides, Polyox ® polyethylene oxides (m. wt.
  • AquaKeep ® acrylate polymers diesters of polyglucan, crosslinked polyvinyl alcohol and poly N-vinyl-2- pyrrolidone, sodium starch glucolate (e.g. Explotab ® , Edward Mandell C. Ltd.), hydrophilic polymers such as polysaccharides, methyl cellulose, sodium or calcium carboxymethylcellulose, nitrocellulose, carboxymethyl cellulose, cellulose ethers, polyethylene oxides (e.g.
  • Polyox® Union Carbide
  • Eudragit®, Rohm and Haas other acrylic acid derivatives, sorbitan esters, natural gums, lecithins, pectin, alginates, ammonia alginate, sodium, calcium, potassium alginates, propylene glycol alginate, agar, and gums such as arabic, karaya, locust bean, tragacanth, carrageens, guar, xanthan, scleroglucan and mixtures and blends thereof.
  • excipients such as plasticisers, lubricants, solvents and the like may be added to the coating.
  • Suitable plasticisers include for example acetylated monoglycerides; butyl phthalyl butyl glycolate; dibutyl tartrate; diethyl phthalate; dimethyl phthalate; ethyl phthalyl ethyl glycolate; glycerin; propylene glycol; triacetin; citrate; tripropioin; diacetin; dibutyl phthalate; acetyl monoglyceride; polyethylene glycols; castor oil; triethyl citrate; polyhydric alcohols, glycerol, acetate esters, gylcerol triacetate, acetyl triethyl citrate, dibenzyl phthalate, diliexyl phthalate, butyl octyl phthalate, diisononyl phthalate, butyl octyl phthalate, dioctyl azelate, epoxidised tallate, triis
  • modified release component comprises a modified release matrix material
  • any suitable modified release matrix material or suitable combination of modified release matrix materials may be used.
  • modified release matrix material includes hydrophilic polymers, hydrophobic polymers and mixtures thereof which are capable of modifying the release of the fluorocytidine derivative dispersed therein.
  • Modified release matrix materials suitable for the practice of the present invention include but are not limited to microcrystalline cellulose, sodium carboxymethylcellulose, hydoxyalkylcelluloses such as hydroxypropyhnethylcellulose and hydroxypropylcellulose, polyethylene oxide, alkylcelluloses such as methylcellulose and ethylcellulose, polyethylene glycol, polyvinylpyrrolidone, cellulose acteate, cellulose acetate butyrate, cellulose acteate phthalate, cellulose acteate trimellitate, polyvinylacetate phthalate, polyalkylmethacrylates, polyvinyl acetate and mixture thereof.
  • the modified release composition according to the present invention may be incorporated into any suitable dosage form which facilitates release of the active ingredient in a pulsatile manner.
  • the dosage form comprises a fluorocytidine derivative-containing particulates which are filled into suitable capsules, such as hard or soft gelatin capsules.
  • the fluorocytidine derivative-containing particulates may be compressed (optionally with additional excipients) into mini-tablets which may be subsequently filled into capsules.
  • Another suitable dosage form is that of a tablet.
  • the fluorocytidine derivative-containing particulates making up the composition of the invention may further be included in rapidly dissolving dosage forms such as an effervescent dosage form or a fast-melt dosage form.
  • the amount of fluorocytidine derivative present in the dosage form is a therapeutically effective amount which will vary according to, among other things, the specific type of cancer being treated, the sensitivity of the patient, as well as other factors known to the skilled artisan. In one embodiment, the amount of fluorocytidine derivative present in the dosage form is from about 0.1 mg to about 1 g, preferably from about 150 mg to about 500 mg.
  • the present invention further provides a method for the treatment of cancer comprising the step of administering a therapeutically effective amount of the composition of the present invention.
  • the composition comprises capecitabine that is delivered in a pulsatile manner.
  • a multiparticulate modified release composition according to the present invention is prepared as follows.
  • capecitabine-containing particles A solution of capecitabine (50:50 racemic mixture) is prepared according to any of the formulations given in Table 1. The capecitabine solution is then coated onto nonpareil seeds to a level of approximately 16.9% solids weight gain using, for example, a Glatt GPCG3 (Glatt, Protech Ltd., Leicester, UK) fluid bed coating apparatus to form the capecitabine- containing particles.
  • Glatt GPCG3 Glatt, Protech Ltd., Leicester, UK
  • Capecitabine containing modified release particles are prepared by coating the capecitabine-containing particles prepared according to Example l(a) above with a modified release coating solution as detailed in Table 2.
  • the capecitabine-containing particles are coated to varying levels up to approximately 30% weight gain using, for example, a fluid bed apparatus.
  • the modified release particles prepared according to Example l(a) and (b) above are encapsulated in size 2 hard gelatin capsules to an overall 150 mg dosage strength using a Bosch GKLF 4000S encapsulation apparatus.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition multiparticulaire à libération modifiée, qui contient un dérivé de fluorocytidine, de préférence la capécitabine, et un constituant à libération modifiée présentant un enrobage à libération modifiée, une substance matricielle à libération modifiée ou les deux. Une fois administrée par voie orale, la composition, en action, libère le dérivé de fluorocytidine d'une manière pulsatile environ six à environ douze heures après administration.
EP06749864A 2005-04-12 2006-04-12 Compositions a liberation modifiee contenant un derive de fluorocytidine pour le traitement du cancer Withdrawn EP1874271A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67050705P 2005-04-12 2005-04-12
PCT/US2006/013629 WO2006110800A1 (fr) 2005-04-12 2006-04-12 Compositions a liberation modifiee contenant un derive de fluorocytidine pour le traitement du cancer

Publications (2)

Publication Number Publication Date
EP1874271A1 true EP1874271A1 (fr) 2008-01-09
EP1874271A4 EP1874271A4 (fr) 2012-01-25

Family

ID=37087358

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06749864A Withdrawn EP1874271A4 (fr) 2005-04-12 2006-04-12 Compositions a liberation modifiee contenant un derive de fluorocytidine pour le traitement du cancer

Country Status (7)

Country Link
EP (1) EP1874271A4 (fr)
JP (1) JP2008535920A (fr)
CA (1) CA2604192A1 (fr)
DE (1) DE112006000873T5 (fr)
ES (1) ES2327195B1 (fr)
GB (1) GB2442615A (fr)
WO (1) WO2006110800A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
US20110027374A1 (en) * 2008-12-16 2011-02-03 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
WO2016203358A1 (fr) * 2015-06-13 2016-12-22 Intas Pharmaceuticals Ltd. Capsules de capécitabine à libération prolongée
JP2020514314A (ja) * 2017-02-06 2020-05-21 インタス ファーマシューティカルズ リミテッド 即時放出及び持続放出カペシタビンを含む組成物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000025752A1 (fr) * 1998-11-02 2000-05-11 Church, Marla, J. Composition a liberation modifiee multiparticulaire
US6110498A (en) * 1996-10-25 2000-08-29 Shire Laboratories, Inc. Osmotic drug delivery system
WO2001037808A1 (fr) * 1999-11-23 2001-05-31 Lipocine, Inc. Excipients solides pour administration amelioree d'ingredients actifs contenus dans des compositions pharmaceutiques
US20010038858A1 (en) * 1994-08-04 2001-11-08 Roser Bruce J. Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US20020019365A1 (en) * 2000-06-02 2002-02-14 Jones Richard E. Pharmaceutical compositions of 2'-deoxy-2'-(fluoromethylene)cytidine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
ATE344670T1 (de) * 2000-02-28 2006-11-15 Pfizer Entpr Sarl Synergistische kombination zur behandlung von kolorektalkarzinom

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010038858A1 (en) * 1994-08-04 2001-11-08 Roser Bruce J. Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6110498A (en) * 1996-10-25 2000-08-29 Shire Laboratories, Inc. Osmotic drug delivery system
WO2000025752A1 (fr) * 1998-11-02 2000-05-11 Church, Marla, J. Composition a liberation modifiee multiparticulaire
WO2001037808A1 (fr) * 1999-11-23 2001-05-31 Lipocine, Inc. Excipients solides pour administration amelioree d'ingredients actifs contenus dans des compositions pharmaceutiques
US20020019365A1 (en) * 2000-06-02 2002-02-14 Jones Richard E. Pharmaceutical compositions of 2'-deoxy-2'-(fluoromethylene)cytidine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2006110800A1 *

Also Published As

Publication number Publication date
EP1874271A4 (fr) 2012-01-25
WO2006110800A1 (fr) 2006-10-19
GB2442615A (en) 2008-04-09
ES2327195A1 (es) 2009-10-26
CA2604192A1 (fr) 2006-10-19
GB0720886D0 (en) 2007-12-05
JP2008535920A (ja) 2008-09-04
DE112006000873T5 (de) 2008-03-06
ES2327195B1 (es) 2010-07-09

Similar Documents

Publication Publication Date Title
US20070122481A1 (en) Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
JP6170896B2 (ja) ５−フルオロシトシン製剤およびその使用
US20070298098A1 (en) Controlled Release Compositions Comprising Levetiracetam
US20060121112A1 (en) Topiramate pharmaceutical composition
WO2008028193A2 (fr) Formulations orales d'analogues de cytidine administrées dans le côlon
KR20080059409A (ko) 즉시방출형 및/또는 조절방출형 특성을 가진 약제학적 제형
WO2006088864A1 (fr) Compositions à libération contrôlée comprenant du lévétiracétam
US20070173464A1 (en) Oral ribavirin pharmaceutical compositions
EP1874271A1 (fr) Compositions a liberation modifiee contenant un derive de fluorocytidine pour le traitement du cancer
CA2609998A1 (fr) Compositions pharmaceutiques orales a base de ribavirine
AU2006209212B2 (en) Controlled release compositions comprising an antipsychotic agent
US20060269596A1 (en) Controlled release compositions comprising an acylanilide
US20200054659A1 (en) Extended release capecitabine capsules
JP2020514314A (ja) 即時放出及び持続放出カペシタビンを含む組成物
AU2013205004A1 (en) Formulations of 5-fluorocytosine and Uses Thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071108

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): FR IE IT

DAX Request for extension of the european patent (deleted)
RBV Designated contracting states (corrected)

Designated state(s): FR IE IT

A4 Supplementary search report drawn up and despatched

Effective date: 20111229

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/14 20060101AFI20111222BHEP

Ipc: A61K 31/7068 20060101ALI20111222BHEP

Ipc: A61K 9/48 20060101ALI20111222BHEP

Ipc: A61K 9/20 20060101ALI20111222BHEP

Ipc: A61K 9/28 20060101ALI20111222BHEP

Ipc: A61K 9/16 20060101ALI20111222BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120728